A Brief History of Immunotoxicology and a Review of the Pharmaceutical Guidelines
- 1 March 2004
- journal article
- autobiography
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 23 (2), 83-90
- https://doi.org/10.1080/10915810490435596
Abstract
This article provides a brief history of the development of the field of immunotoxicology from one individual perspective and separates the discussion into five phases: the methods development and validation phase; the compound testing phase; the many meetings and organization of the specialty section phase; the mechanistic studies phase; and the guidelines phase. During the discussion of each phase, major highlights, accomplishments, contributors and key references are provided. The immunotoxicology guidelines for the testing of pharmaceutical chemical entities across the three major geographic axes are also presented and compared, along with some of the concerns raised by industry with these guidelines. The mandatory requirement of functional tests represents the major concern and difference between the Committee of Proprietary Medicinal Products (CPMP) and the new Food and Drug Administration (FDA) guidance. The scientific basis for the recommendation of the functional tests proposed in the guidance documents based on National Institute of Environmental Health and Safety/National Toxicology Program (NIEHS/NTP)-sponsored studies is described. Experience at Sanofi-Synthelabo, with the testing of 29 new chemical drug entities developed across a broad range of therapeutic classes using this testing paradigm and functional tests to define their immunotoxic potential, yielded a low number of compounds (6.8%) that produced any abnormal reaction. The two positive compounds might have been anticipated based on their pharmacology.Keywords
This publication has 31 references indexed in Scilit:
- Examination of immune parameters and host resistance mechanisms in B6C3F1 mice following adult exposure to 2,3,7,8‐tetrachlorodibenzo‐p‐dioxinJournal of Toxicology and Environmental Health, 1990
- Suppression of cytolytic function in murine lymphocytes exposed to 1,4-bis [(2-aminoethyl)amino]-5, 8-dihydroxy-9,10-anthracenedione dihydrochloride (AEAD): Inhibition of proliferation by cytotoxic T-lymphocyte precursorsInternational Journal of Immunopharmacology, 1989
- Suppression of murine cytotoxic T-lymphocyte induction following exposure to 7,12-dimethylbenz[a]anthracene: Dysfunction of antigen recognitionInternational Journal of Immunopharmacology, 1989
- Effects of 7,12-dimethylbenz[a]anthracene, benzo[a]pyrene and cyclosporin A on murine cytomegalovirus infection: Studies of resistance mechanismsInternational Journal of Immunopharmacology, 1988
- Suppression of T-helper cell function in mice following exposure to the carcinogen 7,12-dimethylbenz[a]anthracene and its restoration by interleukin-2International Journal of Immunopharmacology, 1987
- Effect of short-term inhalation exposure to 1,3-butadiene on murine immune functionsToxicology and Applied Pharmacology, 1986
- Immunosuppression following 7,12-dimethylbenz[a]anthracene exposure in B6C3F1 mice—II. Altered cell-mediated immunity and tumor resistanceInternational Journal of Immunopharmacology, 1986
- The effects of orthophenylphenol, tris(2,3-dichloropropyl) phosphate, and cyclophosphamide on the immune system and host susceptibility of mice following subchronic exposureToxicology and Applied Pharmacology, 1981
- Examination of bone marrow, immunologic parameters and host susceptibility following pre- and postnatal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)International Journal of Immunopharmacology, 1980
- Assessment of Immunobiological Effects Induced by Chemicals, Drugs or Food additives. I. Tier Testing and Screening ApproachDrug and Chemical Toxicology, 1979